Browse courses by:
By: Rishi P. Singh, MD; Dean Eliott, MD; Philip Ferrone MD; and Szilárd Kiss, MD.
This course has expired. You can still review the content but course credit is no longer available.
LEARNING OBJECTIVES:
At the end of this activity, participants will be able to:
Advancements in treatment possibilities and technology have amplified the opportunity for improved outcomes for many vitreoretinal diseases. Results from new research is continuously adding to the available evidence in helping inform management approaches for treatment of retinal diseases. The clinical management of retinal diseases, such as AMD and DME, continues to evolve rapidly as novel therapies and new clinical trial outcomes expand and refine practice patterns. Retina specialists and comprehensive ophthalmologists are faced with the challenge of understanding and implementing the most up-to-date information as presented to them within the literature and at meetings. Like other medical professionals, ophthalmologists routinely turn to expert colleagues for knowledge that will help them to develop the most effective therapeutic strategies.
Although new treatments may be approved for disease states and presented study outcomes may demonstrate statistical significance, clinicians may not have access to the methodology or limitations of the information. Expert opinions regarding emerging clinical data can help close the learning and practice gap, allowing more patients to benefit from technology advancements that can improve treatment outcomes.
This CME activity will provide expert, prospective knowledge from a panel of vitreoretinal specialists. This panel of experts will examine the latest topics in retina, weigh the evidence, clarify the latest information and deliberate its validity and impact on the optimal management of the related retinal diseases. The activity will also provide expert opinion to help clinicians plan for near-term future developments in this area.
DISCLOSURE POLICY:
In accordance with the disclosure policies of the Dulaney Foundation and to conform with ACCME and US Food and Drug Administration guidelines, anyone in a position to affect
the content of a CME activity is required to disclose to the activity participants (1) the existence of any financial interest or other relationships with the manufacturers of any commercial products/devices or providers of commercial services and (2) identification of a commercial product/device that is unlabeled for use or an investigational use of a product/
device not yet approved.
DISCLAIMER:
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of The Dulaney Foundation, Avlis International, Inc., or Regeneron Pharmaceuticals.